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was 93.3% at 19 months and 81.6% estimated at ﬁve years. Disease-free survival at mean follow-up was 89.7% and 74.4% 5 years.
Rectal, urinary and vaginal late toxicity was moderate (CTC grade 2: 5.5%, 5.5% and 17.5% respectively). OS was signiﬁcantly
worse in patients with para-aortic disease compared with those without disease (p<0.000) and in patients with prolonged (>8
weeks) radiation treatment (p=0.022). 25 patients complete QLQ C30, QLQ CX24 and IFSF as measures of quality of life and sexual
function with mean scores of 3.45/4 and 3.07/4 although IFSF mean score was 1.84/5.
Conclusions. Laparoscopic extraperitoneal aortic lymphadenectomy is a feasible procedure, which identify patients with para-
aortic disease tailoring their treatment. The addition of para-aortic external radiation therapy seems to be well tolerated by the
patients, with apparently no inﬂuence in quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.242
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Introduction. The uterine cervical carcinomas remain a health problem with poor survival rates and low rates of local and dis-
tant control. The use of 3D conformal radiotherapy (RTC3D) associated with concomitant chemotherapy (CT) utilizes a same
therapeutic approach all the advantages of a multimodal treatment.
Objective. To perform a descriptive analysis end, a phase II study with QT induction RTC3D/QT and BRT/surgery effort.
Material and methods. Between February 1999 and April 2009 a total of 139 patients diagnosed with uterine cervical carcinoma
were included. The mean age was 58 years (range 29–78). Stage distribution was: IB2 (5.75%), IIA (5.03%), IIB (40.3%), IIIA (2.9%),
IIIB (31.6%), IV (7.91%) and no visceral IVB (6.47%). -Scheme of chemotherapy: a) A CT cycle induction Cisplatin 75mg/m2 and
750mg/m2 Tegafur. Concomitant CT: Cisplatin 25mg/m2 weekly and Tegafur 450mg/m2. - Scheme of Radiotherapy: Virtual
simulation and 3-D planning. The total dose was 45–50.4Gy.
Results. A total of 139 patients were performed until December 2012. With a median follow-up of 110 months (range 46–168
months) are still Alive (49.6%), Exitus (50.4%). Overall survival: by stages: IB2 (62.5%), IIA (85.7%), IIB (67.8%), IIIA (75%), IIIB (27.2%),
IV A (36%), IV B (11.1%). Responses: CR 96 (69.1%), PR 31 (22.3%), ED1 patient (0.7%), PD 1 patient (0.7%), NA (7.2%). Proﬁle of
Recurrence: local (38), regional (37), remote (22), para-aortic note 9. Severe acute toxicity: hematologic 7.9%, gastrointestinal
5.7%, gynecological 2.9%, vascular 4.3%, other 2.9%. Severe chronic toxicity: retroperitoneal ﬁbrosis 4.3%, gastrointestinal 2.9%,
urological 1.4%, other 2.4%. Exitus: 4 patients: In patients surviving longer submitted 9 secondary neoplasms.
Conclusions. The survival for stages IB2 to IIIA is high of 62.5 to 85.7%. In IIIB to IVA is around 36% and 11.1% and the of percetntage
loco – regional recurrence is high. Toxicity is manageable.
http://dx.doi.org/10.1016/j.rpor.2013.03.243
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Purpose. To analyze retrospectively the outcome of patients with cervical cancer treated with external beam radiotherapy (EBR)
and high-dose-rate (HDR) brachytherapy.
Methods and materials. From November 2002 to November 2012, 89 patients with FIGO Stages IB to IVB were treated. The mean
patient age was 53 years. Most frequently used EBR dose to the whole pelvis (with or without paraortic nodes included) was 45Gy
in 25 fractions. Parametrial or bulky lymph node (LN) boost was performed in 11.2% of patients. Brachytherapy with HDR was
performed during EBR or following its completion with ﬁve weekly fractions of 5.5–6Gy to point A. Within the EBR, 79 of the 89
patients (88%) received concomitant chemotherapy (weekly cisplatin: 52 patients or taxol: 27 patients). Patient age, tumor stage,
LN metastases, para-aortic LN sampling and histology were variables analyzed for survival and local control; whereas, doses at
organ risk were variables for analyzing late toxicity. Initially plain X-ray ﬁlm simulation was the standard of care, but further in
time, CT planning was performed. Doses at the rectum and bladder ICRU reference points were calculated for the ﬁrst, and D2cc
bladder, rectum and sigmoid were calculated for the second.
Results. Median follow-up time was 33 months. Three patients had stage I disease (3.3%); 44 stage II disease (49.5%); 32 stage III
disease (36%) and 10 stage IV (11.2%). Five patients (6%) suffered local failure, 5 pelvic nodal failure (6%) and 21 (25%) distant
metastases. Overall survival, disease-free survival, and loco-regional control at 5 years was 68.8%, 59.2%, and 81.9% respectively.
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The actuarial late complication rate grade 3 was 1.1% for the bladder and 3.4% for the bowel and rectum. One patient suffered a
GI grade 4 complication. Vagina shortening and obliteration occurred in 18.8%.
Conclusions. This series suggests that 45Gy to the whole pelvis combined with ﬁve fractions of 5.5–6Gy to point A with HDR
brachytherapy in conjunction with concomitant chemotherapy is an effective and safe fractionation schedule in the treatment
of stages IB to IVB of cervix cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.244
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Purpose. Undifferentiated Uterine Sarcoma (UUS) is a rare, not well known and aggressive disease. We retrospectively analysed
the outcome of 13 patients diagnosed and treated at our centre.
Material and methods. From 1979 to 2010 the records and pathology of 13 patients diagnosed and treated for UUS were retrospec-
tively analysed. Three patients had metastasis at diagnosis; 10 out 13 patients underwent surgery with a curative aim followed by
radiation therapy (RT) in 8 patients (external beam radiotherapy and/or brachytherapy). Chemotherapy (ChT) was administered
as an adjuvant treatment in 3 patients. The Kaplan–Meier actuarial method was used to analyse the overall survival (OS) and a
descriptive analysis was used to know the frequencies.
Results. Median follow-up of the entire series was 16 months (2–276 months, mean 50,08). The mean age of the group was 66 years.
FIGO 2009 stage: 3 IA, 5 IB, 2 IIB and 3 IVB. Patients with stage I developed 2 local relapses (in the only 2 no irradiated patients)
and 3 distant metastasis; 50% of this group were long survivors. All patients in stage II developed distant metastasis. Distant
metastasis was observed in 61.5% of the entire series. A half of patients treated with adjuvant RT were alive at the moment of
the analysis, and no evidence of local relapse was viewed. The 3 patients that received adjuvant ChT died because progression of
the disease (median survival 12 months). The median OS was 16 months (mean 77,8); for stage I was 17 months, being 9 months
in the remaining patients (mean 126 vs14).
Conclusions. Poor outcome of UUS was associated with a high incidence of distant metastasis. Stage was the strongest predictor
of bad outcome. Adjuvant RT seems to beneﬁt these patients with 50% of long survivors. New treatment strategies should be
considered in patients in whom distant metastasis are not found at diagnosis.
http://dx.doi.org/10.1016/j.rpor.2013.03.245
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Introduction. Intracavitary brachytherapy, an essential part of any deﬁnitive treatment of locally advanced cervical cancer, is
associated to aches andpain of varying intensity. For the proper insertion of devices as applicators, it is essential to immobilize the
patient, the tumour and the surrounding organs. The presence of anaesthesiologists in Brachytherapy Units is strictly necessary.
Objectives. Evaluate the anaesthetic procedure in gynaecologic intracavitary brachytherapy in cervical cancer as standard practice.
Material and methods. 33 patients with locally advanced cervical cancer underwent to high dose rate Ir192 (HDR) gynaecologic
intracavitary brachytherapy between 2010/2011. Median age was 55.81 (34–82) and 132 fractions. Patients were examined in the
preanaesthesia consultation and signed the informed consent. The majority were classiﬁed based on the American Society of
Anestesiologist (ASA) III (63,64%). Anaesthetic technique chosen was total intravenous anaesthesia (TIVA), induction and main-
tenance with propofol and remifentanil/fentanyl to maintain hemodynamic stability and the adequate degree of immobilization.
Spontaneous ventilation with face masks or laryngeal mask (LM) or mechanical ventilation with LM or orotracheal intubation
was used. 11% required the use of muscular relaxants. Patients were transferred to the simulation room, and then moved to the
isolation room for treatment.
Results. At the end of the procedure, patients were lucid, supportive and without pain. No patient experienced nausea or vomi-
ting nor required additional analgesia in the surgical room. They did not present any acute nor late complications related to
anaesthesia. TIVA is well tolerated and provides good anaesthetic quality.
Conclusions. TIVA based on propofol and remifentanilo has a safety proﬁle, fast metabolism and elimination. It is adequate
technique for short procedure such as intracavitary gynaecologic brachytherapy on an outpatient basis and no complications
were observed. Standard criteria for medical discharge are met at an earlier stage, signiﬁcantly shortening the patient’s stay at
the hospital and minimize costs.
http://dx.doi.org/10.1016/j.rpor.2013.03.246
